H3B-6545-G000-102, NCT04288089: A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer |
|
|
| Active, not recruiting | 1 | 31 | Europe, US | Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg) | Eisai Inc. | Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms | 09/22 | 08/24 | | |
